The Body As A Bioreactor – The Execution

If the body becomes the bioreactor, the harder question may be what has to be built around it. In this third episode of the series, the focus moves from therapeutic promise to execution: how manufacturing, infrastructure, and regulation may need to change as genomic medicines move away from centralized facilities. The conversation considers what a shift away from complex ex vivo operations could mean for production closer to patients, why manufacturing may need to scale toward both global populations and individual patients, and how consistency can hold across different environments. It also asks what a new framework for trust might require from quality and testing approaches.

Hear how infrastructure could shape who gets access to in vivo therapies.